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The manuscript describes design and synthesis of novel oxadiazolyl-2-oxoindolinylidene 
propane hydrazides as amide tethered hybrids of indole and oxadiazole and their evaluation for anti-
inflammatory and analgesic activity. The compounds were synthesized following five step reaction 
to yield fifteen derivatives as 3-(5-substituted-1,3,4-oxadiazol-2-yl)-N’-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]propane hydrazides. The final derivatives 3-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-
2-yl]-N’-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]propane hydrazide and 3-[5-(4-methylphenyl)-
1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]propane hydrazide were found 
to be highly promising molecules with severity index of 0.35 and 0.56, respectively, which is 
promising for an analgesic compound. The hydroxy and methyl substitution on phenyl ring system 
provided with active anti-inflammatory compounds having increase in reaction time of 84.11 and 
83.17%, respectively compared to standard drug at 85.84%. Molecular docking studies exhibit 
comparable interaction with synthesized derivatives and standard drug having a dock score of 
−4.44 by the K-nearest neighbour genetic algorithm method.
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Introduction
Discovery of new molecules within a short possible time 
has become a focal point in current medicine. Need for new 
and better drugs with less toxicity and more selectivity are 
major criteria for the designing of a molecule. Recently, 
many new approaches are observed to be practiced for 
development of newer biologically active molecules. Special 
focus is given on structure based drug discovery, fragment 
based drug discovery, protein-protein interaction inhibitor 
study, proteomics and pharmacogenomics and these are 
becoming more and more popular to medicinal chemists.1 
Still the earlier methods are persistent and yielding good 
results in form of newer and safer molecules. One of such 
approach is hybrid approach.2 It involves development 
of better, synergistic molecules on hybridization of two 
or more active biomolecules or ligands to develop newer 
derivative that possess good pharmacological activity. 
The success of this approach has been unequivocal with 
reports of development of anticancer hybrid agents, 
several nonsteroidal anti-inflammatory drugs (NSAIDs) 
and antiviral agents. Many drugs that are developed on 
basis of hybrid approach are used in therapy today and 
many more are in pipelines and yet to come on market. 
The success of hybrid approach is depicted by 
several molecules such as cediranib, which is a hybrid 
of quinazoline and indole; ateviridine, a hybrid of 
pyridine and indole; indalpine, a hybrid of indole; and 
Kerzare et al. 1999Vol. 27, No. 11, 2016
piperazine and pravadoline, which is a hybrid of indole 
and morpholine, respectively (Figure 1). The success of 
this approach is well defined in discovery of NSAIDs such 
as the pravadoline, which acts as cyclooxygenase (COX) 
inhibitor but also exhibit a potent cannabinoid agonist 
effect.3 The need for efficient and nontoxic NSAIDs 
has made us to design and develop newer and better 
molecules. The unwanted gastrointestinal (GI) ulceration, 
bleeding, nephrotoxicity observed in conventional COX 
inhibitors and the failure of selective COX inhibitors due 
to adverse cardiac effects suggest for better drugs devoid 
of these severe side effects.4 In view of this scenario, it was 
decided to employ the hybrid approach for development of 
novel molecules for their analgesic and anti-inflammatory 
activity. To achieve this goal, we selected to design and 
synthesize a hybrid molecule from indole and oxadiazole 
nuclei. Indole derivatives have been found to exhibit 
variety of pharmacological activities and have raised 
considerable interest because of their potential beneficial 
effects on human health.5,6 They have been reported 
to possess antibacterial,7 anticonvulsant,8 antifungal,9 
antiviral,10 anticancer11 and anti-inflammatory12 properties. 
Figure 1. Examples describing success story of hybrid approach in drug discovery.
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Indole derivative such as indomethacin is an established 
NSAID but it cause severe gastrointestinal side effect. 
The oxadiazole is found to poses versatile activity 
like the antiviral, anticancer and anticystic activity; 
compounds bearing 1,3,4-oxadiazole nucleus are also 
known to exhibit unique antiedema and anti-inflammatory 
potential.13 In the past, many indole and 1,3,4-oxadiazole 
derivatives showed potential for anti-inflammatory and 
analgesic activity in animal model of inflammation 
and pain.14-18
Compound 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63
R H p-OH p-CH3 m-NO2 o-OCH3, m’-OCH3 p-Cl p-NO2 p-COCH3 p-F o-Cl o-NO2 m-Cl o-F p-Br m-Br
Scheme 1. Synthesis of N’-(2-oxoindolin-3-ylidene)-3-(5-substituted phenyl-1,3,4-oxadiazol-2-yl)propane hydrazide derivatives 49-63.
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The need for newer drug molecule and success of 
hybrid approach compelled us for development of some 
new NSAIDs. The target moieties selected for formation 
of a hybrid drug was based on our previous literature 
study, and it was found that indole and oxadiazole nuclei 
possess analgesic and anti-inflammatory properties and 
thus it was found worth to prepare a hybrid derivative from 
these moieties. To achieve this goal, we synthesized fifteen 
different hybrids of indole and oxadiazole as 5-substituted-
1,3,4-oxadiazole-2-yl-(2-oxo-1,2-dihydro-indol-3-ylidene) 
propane hydrazide derivatives. Scheme 1 explains the 
synthesis of these derivatives that involves two different 
steps. In the first step, substituted aryl acid hydrazides 
were obtained from various substituted benzoic acids with 
formation of intermediate benzoates. In the second step, the 
indole-2,3-dione was reacted with hydrazine hydrate to form 
isatin-3-hydrazone, which in the subsequent reaction with 
succinic anhydride produces indolyl hydrazinyl butonic acid. 
This acid on reaction with substituted aryl acid hydrazides 
obtained from earlier steps yields the final derivatives as 
substituted oxadiazolyl indolyl propane hydrazides. 
These newly synthesized compounds were tested 
initially for their in vitro characteristic as active or inactive 
molecules by the egg albumin denaturation test.19 Further, 
these compounds were subjected for their analgesic and anti-
inflammatory activity by the carrageenan induced rat paw 
edema model20 and Eddy’s hot plate method,21 respectively. 
After evaluation for pharmacological studies, it becomes 
necessary to determine the safety of synthesized compounds 
with respect to ulcerogenesis study or the determination 
of severity index with respect to reference drug such as 
indomethacin. Further, to determine the possible interaction 
of most potent compound and receptor in silico, studies need 
to be carried out. This was achieved by molecular docking 
studies of the ligands on the COX-II receptor.22,23 
The series of final derivatives N’-(2-oxoindolin-3-
ylidene)-3-(5-substituted phenyl-1,3,4-oxadiazol-2-yl) 
propane hydrazides 49-63 as described in this study 
is outlined in Scheme 1. The products were obtained 
following two different steps; in the first step various 
substituted benzoic acids 1-15 were obtained commercially; 
these substituents were reacted with ethanol in presence 
of sulphuric acid to derive corresponding benzoates 16‑30 
under conditions of nucleophilic substitution reaction. 
These benzoates were further treated with hydrazine 
hydrate to yield various substituted aryl acid hydrazides 31-
45, which were further employed in the reaction system. In 
the second step to the reaction scheme, isatin 46 was treated 
with hydrazine hydrate under ambient conditions to yield 
the isatin-3-hydrazone 47. It was further substituted by 
succinic anhydride to yield the oxoindolyidene hydrazinyl 
butanoic acid 48. Up to this moiety, the step two provides 
with reactant for the final reaction, in which the various 
substituted aryl acid hydrazides 31-45 and oxoindolyidene 
hydrazinyl butanoic acid 48 react to undergo the cyclization 
reaction in presence of phosphorous oxychloride, yielding 
various N’-(2-oxoindolin-3-ylidene)-3-(5-substituted 
phenyl-1,3,4-oxadiazol-2-yl) propane hydrazides 49-63 
in 40-80% yield. 
Experimental
Materials and methods
Chemicals were obtained from Sigma-Aldrich 
(St. Louis, MO, USA), S D Fine-Chem (Mumbai, MH, 
India) and Merck (Darmstadt, Germany), unless specified. 
Melting points (m.p.) were detected with open capillaries 
using ThermoNik precision melting point cum boiling point 
apparatus (model C-PMB-2, Mumbai, MH, India) and are 
uncorrected. Infrared (IR) spectra (KBr) were recorded 
on FTIR-8400s spectrophotometer (Shimadzu, Tokyo, 
Japan) at the Department of Pharmaceutical Sciences, 
Rashtrasant Tukadoii Maharai (RTM) Nagpur University. 
Proton (1H) and carbon 13 (13C) nuclear magnetic resonance 
(NMR) were obtained using a Bruker Avance II 400 MHz 
spectrometer (Billerica, MA, USA), using tetramethylsilane 
(TMS) as internal standard. All chemical shift values were 
recorded as d (ppm), coupling constant value J is measured 
in hertz, the peaks are presented as s (singlet), d (doublet), 
t (triplet), brs (broad singlet), dd (double doublet), m 
(multiplet). The purity of compounds was controlled by 
thin layer chromatography (silica gel HF254e361, type 
60, 0.25 mm; Merck, Darmstadt, Germany). Electrospray 
ionization mass spectrometry (ESI-MS) was recorded at 
Waters Q-TOF spectrometer (Waters, Milford, MA, USA) 
at the Sophisticated Analytical Instrumentation Facility 
(SAIF), Punjab University (Chandigarh, PB, India).
Synthesis
General methods for synthesis of substituted ethyl 
benzoates (16-30)24
To a solution of substituted benzoic acid (1-15) 
(0.246 mol) in dry ethanol (2.5 mol), concentrated sulphuric 
acid (0.5 mL) was added. The reaction mixture was refluxed 
for 8 h. Excess of ethanol was distilled off and the content 
was allowed to cool. The residue was poured into separating 
funnel containing 60 mL of water. Carbon-tetrachloride 
(5-10 mL) was added to obtain sharp separation of aqueous 
and ester layer. Ester layer was washed with sodium 
hydrogen carbonate solution. The esters (16-30) were 
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collected and recrystallized from ethanol. Details of these 
compounds are available in Supplementary Information. 
General methods for synthesis of substituted aryl acid 
hydrazides (31-45)24
The substituted ethyl benzoates (16-30) (0.01 mol) 
dissolved in dry ethanol (25 mL), hydrazine hydrate (99%, 
0.01 mol) was added and the mixture was refluxed for 6 h. 
The reaction mixture was cooled and the solid obtained was 
filtered and recrystallized from dilute ethanol or from water. 
Details of these compounds are available in Supplementary 
Information.
Procedure for synthesis of 3-hydrazinylidene-1,3-dihydro-
2H-indol-2-one (47)25
A mixture of isatin (46) (1 mmol) and hydrazine hydrate 
(99%, 0.055 g, 1.1 mmol) in absolute methanol (25 mL) was 
refluxed for 1 h and then cooled to room temperature. The 
precipitate of hydrazones was filtered and dried. The crude 
product was recrystallized from ethanol to give hydrazones (47).
Yield: 1.0 g (70%); m.p. 248-250 ºC; Rf 0.39 
(methanol:toluene, 1:4); IR (KBr) ν / cm−1 3411, 2916, 
1655, 1618; 1H NMR (DMSO) d 7.63 (s, 1H, Ar−H), 7.45 
(s, 1H, Ar−H), 7.31 (s, 1H, Ar−H), 7.20 (s, 1H, Ar−H), 
7.0 (s, 1H, NH), 3.34 (s, 2H, NH); 13C NMR (100 MHz, 
DMSO-d6) d 166.25, 152.64, 130.73, 125.24, 120.75, 
120.61, 117.55, 78.81; EI-MS m/z [M + H]+ 162.24.
Procedure for synthesis of 4-oxo-4-[2-(2-oxo-1,2-dihydro-
3H-indol-3-ylidene)-hydrazinyl]butanoic acid (48)26
The mixture of compound (47) (0.01 mol), succinic 
anhydride (0.01 mol) and trimethylamine (1 mmol) in 
dichloromethane (DCM) was stirred at room temperature 
for 3 h and diluted with DCM. The solution was washed 
with sodium bicarbonate and brine twice. The product 
thus obtained was dried over sodium sulphate and the 
excess of solvent was distilled off. The resulting solid was 
recrystallized from ethanol. 
Yield: 0.08 g (80%); m.p. 238-240 ºC; Rf 0.58 (toluene); 
IR (KBr) ν / cm−1 3394, 3059, 2916, 1655, 1618; 1H NMR 
(DMSO) d 12.44 (s, 1H, OH), 7.99 (t, 1H, J 6.7 Hz, Ar−H), 
7.97 (s, 1H, Ar−H), 7.44 (d, 1H, J 8.2 Hz, Ar−H), 7.31 
(d, 1H, J 7.2 Hz, Ar−H), 6.30 (s, 1H, NH), 3.78 (s, 2H, CH2), 
2.23 (s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) d 166.22, 
157.59, 148.41, 131.35, 126.12, 123.58, 121.71, 120.58, 
118.78, 106.41, 51.01, 30.31; EI-MS m/z [M + H]+ 262.04.
General procedure for synthesis of 3-(5-substituted-1,3,4-
oxadiazol-2-yl)-N ’-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]
propane hydrazide derivatives (49-63)27
To a solution of compound (31-45) (0.01 mol) in 
phosphorous oxychloride (15-20 mL), compound (48) 
(0.01 mol) was added. The reaction mixture was refluxed 
for 5 h. The mixture was cooled to room temperature and 
poured onto crushed ice and neutralized the contents with 
sodium hydroxide solution (1 mol L−1). The product was 
filtered, washed with water, dried and recrystallized using 
methanol to get 49-63.
3-(5-Phenyl-1,3,4-oxadiazol-2-yl)-N ’-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]propane hydrazide (49)
Yield: 2.03 g (78%); m.p. 208-210 ºC; Rf 0.83 
(chloroform); λmax 448 nm; IR (KBr) ν / cm−1 3254, 
3059, 2916, 1655, 1618; 1H NMR (DMSO) d 8.91 (s, 1H, 
Ar−H), 8.59 (s, 1H, Ar−H), 8.0 (s, 1H, Ar−H), 7.98 (d, 2H, 
J 7.9 Hz, Ar−H), 7.76 (t, 2H, J 8.3 Hz, Ar−H), 7.45 (dd, 1H, 
J 7.4 Hz, Ar−H), 7.32 (dd, 1H, J 7.6 Hz, Ar−H), 3.58 (s, 2H, 
CH2), 2.38 (s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) 
d 160.53, 156.17, 148.33, 131.52, 126.20, 123.76, 121.78, 
120.72, 33.98; EI-MS m/z [M + H]+ 362.58; anal. calcd. 
for C19H15N5O3: C, 63.1; H, 4.15; N, 19.37; found: C, 63.3; 
H, 4.17; N, 19.39. 
3-[5-(4-Hydroxyphenyl)-1,3,4-oxadiazol-2-yl]-N ’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (50)
Yield: 2.08 g (80%), m.p. 210-212 ºC; Rf 0.8 
(chloroform); λmax 442 nm; IR (KBr) ν / cm−1 3585, 3211, 
2849, 2978, 1711, 1605; 1H NMR (DMSO) d 9.49 (s, 1H, 
OH), 7.72 (t, 2H, J 6.9 Hz, Ar−H), 7.40 (t, 2H, J 8.1 Hz, 
Ar−H), 7.21 (t, 1H, J 6.9 Hz, Ar−H), 7.18 (d, 1H, J 7.4 Hz, 
Ar−H), 6.65 (t, 1H, J 7.8 Hz, Ar−H), 6.36 (s, 1H, Ar−H), 
2.31 (s, 2H, CH2), 1.23 (s, 2H, CH2); 13C NMR (100 MHz, 
DMSO-d6) d 166.11, 162.44, 157.29, 153.76, 137.59, 
132.14, 128.25, 126.72, 122.81, 115.18, 112.36, 102.89, 
50.84, 23.17; EI-MS m/z [M + H]+ 378.11; anal. calcd. for 




Yield: 1.82 g (70%); m.p. 200-202 ºC; Rf 0.47 
(chloroform); λmax 357 nm; IR (KBr) ν / cm−1 3249, 2849, 
2918, 1614, 1598; 1H NMR (DMSO) d 7.75 (t, 1H, J 8.1 Hz, 
Ar−H), 7.46 (t, 1H, J 7.6 Hz, Ar−H), 7.34 (t, 1H, J 5.9 Hz, 
Ar−H), 7.19 (d, 1H, J 7.8 Hz, Ar−H), 7.02 (m, 2H, J 7.9 Hz, 
Ar−H), 6.82 (t, 1H, J 8.4 Hz, Ar−H), 6.43 (s, 1H, Ar−H), 
3.34 (s, 4H, CH2), 2.32 (s, 3H, CH3); 13C NMR (100 MHz, 
DMSO-d6) d 166.37, 166.05, 162.55, 158.97, 153.97, 152.79, 
137.52, 133.74, 130.88, 128.22, 126.76, 122.81, 120.82, 
117.68, 113,56, 112.36, 102.79, 55.90, 54.94, 23.20; EI-MS 
m/z [M + H]+ 376.31; anal. calcd. for C20H17N5O3: C, 64.1; 
H, 4.6; N, 18.7; found: C, 64.6; H, 4.8; N, 18.91.
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3-[5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (52)
Yield: 1.87 g (72%); m.p. 248-250 ºC; Rf 0.72 
(chloroform); λmax 447 nm; IR (KBr) ν / cm−1 3084, 2918, 
1655, 1618, 1529; 1H NMR (DMSO) d 8.31 (s, 1H, Ar−H), 
7.87 (d, 2H, J 7.3 Hz, Ar−H), 7.61 (t, 2H, J 8.4 Hz, Ar−H), 
7.21 (t, 2H, J 7.9 Hz, Ar−H), 6.62 (s, 1H, Ar−H), 3.63 
(s, 2H, CH2), 2.34 (s, 2H, CH2); 13C NMR (100 MHz, 
DMSO-d6) d 165.75, 163.11, 155.20, 147.82, 143.43, 
137.15, 133.34, 130.43, 127.01, 124.34, 123.33, 123.02, 
122.80, 121.50, 112.37, 101.87, 51.03, 23.38; EI-MS m/z 
[M + H]+ 407.72; anal. calcd. for C19H14N6O5: C, 56.3; H, 
3.5; N, 20.77; found: C, 56.5; H, 3.8; N, 20.79.
3-[5-(2,3-Dimethoxyphenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-
oxo-1,2-dihydro-3H-indol-3-ylidene]propane hydrazide (53)
Yield: 2.16 g (83%); m.p. 230-232 ºC; Rf 0.69 
(chloroform); λmax 325 nm; IR (KBr) ν / cm−1 3293, 2918, 
1655, 1618, 2835, 1425; 1H NMR (DMSO) d 7.73 (s, 1H, 
Ar−H), 7.21 (d, 2H, J 8.4 Hz, Ar−H), 7.19 (s, 1H, Ar−H), 
7.05 (s, 1H, Ar−H), 6.76 (t, 1H, J 7.9 Hz, Ar−H), 6.66 
(s, 1H, Ar−H), 4.07 (t, 2H, J 7.9 Hz, CH2), 3.34 (t, 2H, 
J 8.4 Hz, CH2), 2.50 (s, 3H, O−CH3), 1.22 (d, 3H, J 7.8 Hz, 
O−CH3); 13C NMR (100 MHz, DMSO-d6) d 165.64, 
162..36, 153.50, 147.05, 146.48, 137.67, 132.76, 126.71, 
122.80, 119.49, 115.51, 112.52, 111.62, 102.97, 56.38, 
55.57, 23.08, 14.13; EI-MS m/z [M + H]+ 422.14; anal. 
calcd. for C21H19N5O5: C, 59.9; H, 4.52; N, 16.65; found: 
C, 59.5; H, 4.8; N, 16.69.
3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (54)
Yield: 1.12 g (43%); m.p. 240-244 ºC; Rf 0.66 
(chloroform); λmax 452 nm; IR (KBr) ν / cm−1 3239, 2843, 
1713, 1547, 2902; 1H NMR (DMSO) d 8.98 (s, 1H, Ar−H), 
8.59 (s, 1H, Ar−H), 8.0 (d, 2H, J 8.1 Hz, Ar−H), 7.75 
(t, 2H, J 7.9 Hz, Ar−H), 7.45 (dd, 1H, J 7.4 Hz, Ar−H), 7.32 
(dd, 1H, J 7.9 Hz, Ar−H), 3.50 (s, 2H, CH2), 2.31 (s, 2H, 
CH2); 13C NMR (100 MHz, DMSO-d6) d 160.56, 156.15, 
148.33, 131.50, 126.72, 126.21, 123.77, 121.79, 120.72, 
115.25, 51.01, 33.92; EI-MS m/z [M + H]+ 397.32; anal. 
calcd. for C19H14ClN5O3: C, 57.62; H, 3.58; N, 17.71; found: 
C, 57.68; H, 3.62; N, 18.1.
3-[5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (55)
Yield: 2.32 g (89%); m.p. 240-244 ºC; Rf 0.71 
(chloroform); λmax 448 nm; IR (KBr) ν / cm−1 3121, 2916, 
1655, 1618, 2849, 1522; 1H NMR (DMSO) d 8.15 (s, 
1H, Ar−H), 7.74 (q, 1H, J 7.9 Hz, Ar−H), 7.46 (t, 1H, 
J 7.5 Hz, Ar−H), 7.31 (dd, 2H, J 8.2 Hz, Ar−H), 7.21 
(dd, 2H, J 8.4 Hz, Ar−H), 6.68 (s, 1H, Ar−H), 3.35 (s, 2H, 
CH2), 2.51 (s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) 
d 165.71, 163.07, 155.16, 149.14, 147.20, 137.16, 128.28, 
126.96, 123.96, 122.80, 112.24, 101.69, 55.87, 23.37; EI-MS 
m/z [M + H]+ 407.16; anal. calcd. for C19H14N6O5: C, 56.3; 
H, 3.48; N, 20.68; found: C, 56.6; H, 3.5; N, 20.69.
3-[5-(4-Acetylphenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (56) 
Yield: 2.08 g (80%); m.p. 166-170 ºC, Rf 0.65 
(chloroform); λmax 525 nm; IR (KBr) ν / cm−1 3107, 
2918, 1648, 1603, 1210, 2849; 1H NMR (DMSO): d 7.73 
(t, 1H, J 7.4 Hz, Ar−H), 7.49 (d, 1H, J 7.9 Hz, Ar−H), 7.19 
(t, 2H, J 8.5 Hz, Ar−H), 7.03 (d, 1H, J 8.3 Hz, Ar−H), 6.75 
(d, 1H, J 7.4 Hz, Ar−H), 6.65 (s, 1H, Ar−H), 6.37 (s, 1H, 
Ar−H), 3.71 (s, 2H, CH2), 3.35 (s, 2H, CH2), 2.50 (s, 3H, 
CH3); 13C NMR (100 MHz, DMSO-d6) d 200.86, 166.12, 
162.48, 153.70, 147.14, 146.49, 137.65, 132.70, 126.74, 
123.93, 122.80, 119.31, 115.50, 112.50, 111.41, 102.84, 
56.29, 55.58, 50.82, 23.13; EI-MS m/z [M + H]+ 404.09; 
anal. calcd. for C21H17N5O4: C, 62.41; H, 4.23; N, 17.39; 
found: C, 62.48; H, 4.28; N, 17.42.
3-[5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (57) 
Yield: 2.14 g (82 %); m.p. 182-184 ºC, Rf 0.65 
(chloroform), λmax 398 nm, IR (KBr) ν / cm−1 2992, 
2916, 1655, 1605, 1097; 1H NMR (DMSO) d 8.10 
(d, 2H, J 8.3 Hz, Ar−H), 7.68 (t, 2H, J 7.6 Hz, Ar−H), 7.26 
(dd, 1H, J 7.6 Hz, Ar−H), 7.24 (dd, 1H, J 7.3 Hz, Ar−H), 6.81 
(t, 2H, J 6.9 Hz, Ar−H), 3.73 (s, 2H, CH2), 2.50 (s, 2H, 
CH2); 13C NMR (100 MHz, DMSO-d6) d 164.52, 163.31, 
161.31, 160.36, 135.94, 129.96, 129.88, 127.96, 124.35, 
124.17, 115.94, 115.72, 114.50, 103.80, 99.49, 57.01, 
51.68; EI-MS m/z [M + H]+ 380.12; anal. calcd. for 
C19H14FN5O3: C, 60.31; H, 3.71; N, 18.48; found: C, 60.38; 
H, 3.78; N, 18.52. 
3-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (58)
Yield: 1.15 g (43%); m.p. 244-246 ºC; Rf 0.61 
(chloroform); λmax 455 nm; IR (KBr) ν / cm−1 3235, 2843, 
1713, 1537, 2902, 725; 1H NMR (DMSO) d 8.76 (s, 1H, 
Ar−H), 8.31 (s, 1H, Ar−H), 7.92 (d, 2H, J 8.4 Hz, Ar−H), 
7.70 (t, 2H, J 7.6 Hz, Ar−H), 7.43 (dd, 1H, J 7.5 Hz, Ar−H), 
7.30 (dd, 1H, J 7.8 Hz, Ar−H), 3.40 (s, 2H, CH2), 2.53 
(s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) d 164.16, 
154.17, 149.38, 133.60, 125.12, 125.26, 123.77, 121.80, 
121.76, 116.27, 55.10, 34.82; EI-MS m/z [M + H]+ 397.43; 
anal. calcd. for C19H14ClN5O3: C, 57.62; H, 3.58; N, 17.71; 
found: C, 57.68; H, 3.62; N, 18.1.
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3-[5-(2-Nitrophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (59)
Yield: 2.22 g (89%); m.p. 242-244 ºC; Rf 0.71 
(chloroform); λmax 438 nm; IR (KBr) ν / cm−1 3121, 2916, 
1645, 1615, 2749, 1522; 1H NMR (DMSO) d 8.31 (s, 1H, 
Ar−H), 7.87 (d, 1H, J 7.6 Hz, Ar−H), 7.78 (d, 1H, J 7.4 Hz, 
Ar−H), 7.61 (dd, 2H, J 5.3 Hz, Ar−H), 7.21 (t, 2H, J 7.4 Hz, 
Ar−H), 6.72 (t, 1H, J 7.1 Hz, Ar−H), 3.63 (s, 2H, CH2), 2.34 
(s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) d 165.75, 
163.11, 155.20, 147.82, 143.43, 137.15, 133.34, 130.43, 
127.01, 124.34, 123.33, 123.02, 122.80, 121.50, 112.37, 
101.87, 51.11, 23.38; EI-MS m/z [M + H]+ 407.4; anal. 
calcd. for C19H14N6O5: C, 56.3; H, 3.48; N, 20.68; found: 
C, 56.6; H, 3.5; N, 20.69.
3-[5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-N ’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (60)
Yield: 1.1 g (43%); m.p. 235-237 ºC; Rf 0.66 
(chloroform); λmax 432 nm; IR (KBr) ν / cm−1 3229, 2743, 
1713, 1538, 2902, 725; 1H NMR (DMSO) d 8.56 (s, 1H, 
Ar−H), 8.14 (s, 1H, Ar−H), 7.87 (d, 2H, J 8.4 Hz, Ar−H), 
7.65 (t, 2H, J 7.6 Hz, Ar−H), 7.45 (dd, 1H, J 7.5 Hz, Ar−H), 
7.25 (dd, 1H, J 7.8 Hz, Ar−H), 3.35 (s, 2H, CH2), 2.80 
(s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) d 172.16, 
159.17, 144.48, 136.60, 125.16, 123.26, 123.17, 121.85, 
121.70, 117.27, 56.10, 33.83; EI-MS m/z [M + H]+ 397.02; 
anal. calcd. for C19H14ClN5O3: C, 57.62; H, 3.58; N, 17.71; 
found: C, 57.68; H, 3.62; N, 18.1.
3-[5-(2-Fluorophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (61)
Yield: 2.11 g (82 %); m.p. 180-182 ºC, Rf 0.65 
(chloroform), λmax 368 nm, IR (KBr) ν / cm−1 3297, 
2916, 1655, 1605, 1097; 1H NMR (DMSO) d 8.10 
(d, 2H, J 8.3 Hz, Ar−H), 7.68 (t, 2H, J 7.6 Hz, Ar−H), 7.26 
(dd, 1H, J 7.6 Hz, Ar−H), 7.24 (dd, 1H, J 7.3 Hz, Ar−H), 6.81 
(t, 2H, J 6.9 Hz, Ar−H), 3.73 (s, 2H, CH2), 2.50 (s, 2H, CH2); 
13C NMR (100 MHz, DMSO-d6) d 164.52, 163.31, 161.31, 
160.36, 135.94, 129.96, 129.88, 127.96, 124.35, 124.17, 
115.94, 115.72, 114.50, 103.80, 99.49, 57.01, 51.68; EI-MS 
m/z [M + H]+ 380.16; anal. calcd. for C19H14FN5O3: C, 60.31; 
H, 3.71; N, 18.48; found: C, 60.38; H, 3.78; N, 18.52. 
3-[5-(4-Bromophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (62)
Yield: 2.64 g (82%); m.p. 174-176 ºC, Rf 0.65 
(chloroform), λmax 398 nm, IR (KBr) ν / cm−1 2982, 2906, 
1655, 1685; 1H NMR (DMSO) d 8.91 (s, 1H, Ar−H), 8.59 
(s, 1H, Ar−H), 8.0 (s, 1H, Ar−H), 7.98 (d, 1H, J 7.9 Hz, Ar−H), 
7.76 (t, 2H, J 8.3 Hz, Ar−H), 7.45 (dd, 1H, J 7.4 Hz, Ar−H), 
7.32 (dd, 1H, J 7.6 Hz, Ar−H), 3.58 (s, 2H, CH2), 2.38 (s, 2H, 
CH2); 13C NMR (100 MHz, DMSO-d6) d 160.53, 156.17, 
148.33, 131.52, 126.20, 123.76, 121.78, 120.72, 33.98; EI-MS 
m/z [M + H]+ 441.32; anal. calcd. for C19H14BrN5O3: C, 60.31; 
H, 3.71; N, 18.48; found: C, 60.38; H, 3.78; N, 18.52. 
3-[5-(3-Bromophenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide (63)
Yield: 2.15 g (82%); m.p. 175-177 ºC, Rf 0.65 
(chloroform), λmax 395 nm, IR (KBr) ν / cm−1 3392, 2816, 
1635, 1605, 1097; 1H NMR (DMSO) d 8.71 (s, 1H, Ar−H), 
8.61 (s, 1H, Ar−H), 8.21 (s, 1H, Ar−H), 7.88 (d, 1H, 
J 7.9 Hz, Ar−H), 7.66 (t, 2H, J 8.3 Hz, Ar−H), 7.42 (dd, 1H, 
J 7.4 Hz, Ar−H), 7.22 (dd, 1H, J 7.6 Hz, Ar−H), 3.20 (s, 2H, 
CH2), 2.35 (s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) 
d 164.53, 155.17, 148.30, 130.52, 126.25, 125.78, 122.60, 
118.74, 42.61, 33.98; EI-MS m/z [M + H]+ 441.09; anal. 
calcd. for C19H14BrN5O3: C, 60.31; H, 3.71; N, 18.48; found: 
C, 60.33; H, 3.75; N, 18.51. 
Pharmacology 
In vitro evaluation for anti-inflammatory activity by protein 
albumin denaturation method
All synthesized compounds were screened for 
anti-inflammatory activity by using in vitro method 
reported earlier by Mizushima and Kobayashi19 with 
slight modification. Accordingly, inhibition of albumin 
denaturation technique was studied, a 5.0 mL reaction 
mixture was prepared consisting of 0.2 mL of egg albumin 
(obtained from fresh hen’s egg), 2.8 mL phosphate buffered 
saline (pH 6.4) and 2.0 mL of varying concentration of test 
compounds, so that final concentrations become 25, 50, 100 
and 200 μg mL−1. Similar volume of double distilled water 
served as control. Then, the mixtures were incubated at 
37 ± 2 °C in an incubator for 15 min and then heated at 70 ºC 
for 5 min. After cooling, their absorbance was measured at 
660 nm by using vehicle as blank. Indomethacin with final 
concentration of 50 and 100 μg mL−1 was used as reference 
drug and treated similarly for determination of absorbance. 
The reading for this activity was taken on the same day and 
percent inhibition of protein denaturation was calculated 
by equation 1, as follows:
 (1)
In vivo evaluation 
Anti-inflammatory activity
The anti-inflammatory activity was carried out 
according to the method of Halen et al.20 and employed 
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with some modifications.18 Sprague Dawley rats were used 
for this study; seventeen groups with six rats per group 
were formed. All test samples were administered to 
animals at 100 mg kg−1 dosage, as suspension in 0.5% 
carboxymethyl cellulose in water. The samples were 
administered orally; after 60 min of drug dose, injection 
of 0.1 mL solution of carrageenan (0.5 mg 25 mL−1) 
was injected into the sub-plantar tissue of the left hind 
paw of each rat. Out of this, one group was treated with 
standard drug indomethacin (100 mg kg−1). The initial 
volume of paw was measured within 30 s after carrageenan 
injection. Later on paw volume was measured after 1-5 h, 
respectively. The relative increase in the paw volume 
was calculated in the individual animal of the control, 
test, and standard groups, respectively. The percentage 
of inhibition of edema was calculated by the equation 2, 
as follows:
 (2)
where Dt means relative change in paw volume in test 
group and Dc means relative change in paw volume in 
control group.
Analgesic activity
Analgesic activity test was performed following the 
method of Eddy and Leimbach.21 Analgesic activities of 
all synthesized compounds were quantified in vivo by 
Eddy’s hot plate method using analgesiometer. Albino 
wistar mice were used for this study; seventeen groups with 
six rats per group were formed. All the test compounds 
were suspended in 0.5% of carboxymethylcellulose 
sodium (CMC) and administered orally. The albino wistar 
rats were treated with the newly synthesized derivatives 
(100 mg kg−1, p.o.) and standard drug indomethacin 
(100 mg kg−1, p.o.). The animals were individually placed 
on the hot plate maintained at 55 °C, one hour after their 
respective treatments. The response time was noted as the 
time at which animals reacted to the pain stimulus either 
by paw licking or jump response. The relative increase in 
reaction time was measured at an interval of 0, 30, 60 and 
90 min in the individual animal of the control, test and the 
standard group (Table 1). The percent increase in reaction 
time was calculated using equation 3 as follows,
 (3)
where It is the reaction time at time t and Io is the reaction 
time at time zero (0 min). 
Ulcerogenic activity
Acute ulcerogenesis was done according to Cioli et al.28 
and modifications standardized in our laboratory.18 Albino 
rats (150-200 g) were divided into seven different groups 












Inhibition of paw edemab / % Increase in reaction / %
time / h time / min
1 2 3 30 60 90
49 0.0401 61.64 11.6 13.7 13.9 19.45 66.81 71.98 0.24 −3.91
50 0.0409 66.59 35.8 40.9 42.7 35.86 77.11 84.11 0.35 −4.44
51 0.0407 66.19 38.4 43.1 45.5 21.86 76.14 83.17 0.56 −4.37
52 0.0403 65.58 13.4 14.1 14.9 11.92 70.35 81.11 0.52 −3.45
53 0.0402 65.07 30.3 30.5 30.6 24.55 29.72 35.00 NT −4.01
54 0.0398 62.13 20.4 21.2 23.9 27.57 28.52 40.11 NT −3.33
55 0.0403 65.63 20.2 21.4 21.7 26.69 23.91 26.69 NT −3.05
56 0.0401 61.64 35.1 37.6 38.1 21.38 57.81 59.79 NT −3.27
57 0.0402 63.18 35.5 40.0 40.5 44.91 51.12 54.29 NT −3.63
58 0.0403 65.87 21.2 22.6 24.4 20.34 25.33 27.13 NT −1.85
59 0.0397 61.58 33.34 35.56 36.12 27.16 29.12 32.13 NT −2.48
60 0.0373 54.12 22.5 25.8 28.2 21.34 23.33 27.13 NT −0.16
61 0.0403 65.12 23.1 25.2 33.9 11.96 58.35 70.11 0.39 −2.20
62 0.0404 64.16 28.5 31.8 38.2 21.34 23.38 25.13 NT −4.04
63 0.0402 62.13 23.5 24.8 25.2 23.34 24.39 27.13 NT −4.46
Standard drugc 0.0510 82.14 28.5 28.7 46.6 64.27 82.26 85.84 1.25 −4.47
aReadings at 660 nm; bincrease in paw volume measured after 3 h from administration of samples; cindomethacin. NT: Not treated.
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consisting of six animals in each one. Ulcerogenic activity 
was evaluated after p.o. administration of test compounds 
or indomethacin at the dose of 50 mg kg−1. Control rats 
received p.o. administration of vehicle (suspension of 1% 
methyl cellulose in water). Food but not water was removed 
24 h before administration of the test compounds. After 
the drug treatment, the rats were fed normal diet for 17 h 
and then sacrificed. The stomach was removed and opened 
along the greater curvature, washed with distilled water 
and cleaned gently by dipping in saline. Gastric mucosa of 
the rats was examined by means of a four times binocular 
magnifier and the lesions were counted according to earlier 
reported method.18 Accordingly, the mean score of each 
treated group minus the mean score of the control group 
was considered to determine the severity index of gastric 
damage for compounds under study.
Molecular docking study
For docking purpose, the three-dimensional structure 
of COX-2 (protein data bank, PDB code 4Z0L) was 
obtained from RCSB PDB.29 The receptor molecule was 
refined and validated on the basis of Ramchandran plot 
using Biopredicta© module on the Vlife MDS Molecular 
Modeling software, version 4.3.1.22 The Vlife MDS suit 
uses k-nearest neighbour genetic algorithm (KNN-GA) 
method for molecular docking.22 The scoring function is 
based on the basis of best suited moiety for the target with 
respect to energy and inter molecular interactions. The 
ligands that were already present within the receptor in 
bound form were removed to allow for docking protocol. 
All the ligands were prepared and docked for this study in 
flexible docking mode and atoms located within a range 
of 5.0 Å from the amino acid residues were selected in 
the active site. Standard drug indomethacin was also 
included into the series of compounds under study to 
make comparison with respect to in silico analysis. The 
docking calculations and energy minimization were set in 
the Biopredicta© module, most of the parameters were set 
default with 10000 cycles per molecule for the active site 
cavity No. 1. Since this receptor is a homodimer nearly 
all amino acid residues are common in it, the active site 
cavity consisted of amino acid residues GLN374, LEU145, 
TRP139, TYR373, PRO127, ASN375, PRO538, SER541, 
GLY536, ASN537 and PHE142. 
Results and Discussion
The reported investigation deals with synthesis and 
characterization of several hybrid derivatives from indole 
and 1,3,4-oxadiazole nucleuses linked via hydrazide 
chain to form final fifteen derivatives. To achieve these, 
two different steps were carried out to provide with 
substituted aryl acid hydrazides and indolidene hydrazinyl 
butanoic acids, which were further reacted to yield the final 
derivatives. In the first step, various substituted benzoic 
acids 1-15 esterifies in presence of ethanol and concentrated 
sulphuric acid to yield corresponding ethyl benzoates 16-30. 
These compounds were treated with hydrazine hydrate 
to yield the substituted aryl acid hydrazide 31-45. These 
compounds were not characterised on basis of NMR and 
mass analysis because they are reported in literature; hence, 
the physicochemical parameters were used and carry out the 
confirmation of these compounds. All the compounds 16-45 
were analysed on the basis of melting point and TLC and 
found to be in understanding with the reported molecules.
In the second step, isatin (1H-indole-2,3-dione) 46 was 
reacted with hydrazine hydrate in presence of methanol 
under conditions of reflux to yield the 3-hydrazinylidene-
1,3-dihydro-2H-indol-2-one 47. NMR spectra of this 
compound exhibited prominent signals at d 3.34 ppm 
corresponding to the secondary amide proton, the aromatic 
protons belonging to fused benzene ring was exhibited 
around d 7.0 to 7.7 ppm presenting four protons. The 
major spectral change was observed in the IR spectrum 
which provides with an appearance of primary amine 
functional group at 3411.12 cm−1. This structure was 
further confirmed on basis of mass spectral study which 
reflects the molecular weight of 162.24 on the ESI-MS in 
positive mode. In the next step, 47 was reacted with succinic 
anhydride under basic condition in an aprotic solvent 
such as dichloromethane to obtain 4-oxo-4-[2-(2-oxo-1,2-
dihydro-3H-indol-3-ylidene)-hydrazinyl]butanoic acid 48. 
This compound was confirmed on the basis of spectral 
studies; 1H NMR exhibited singlets at d 3.78 and 2.23 ppm 
for four protons belonging to two methylene carbons. The 
proton of hydroxyl group was observed at d 12.44 ppm, 
whereas the protons of secondary amides were observed 
at d 6.30 ppm. The four aromatic protons were reflected 
around d 7.30 to 8.0 ppm for the benzene ring system. This 
was further confirmed from mass spectra in positive mode 
with molecular weight 262.02. 
The final derivatives of this series 3-(5-substituted-
1,3,4-oxadiazol-2-yl)-N’-[2-oxo-1,2-dihydro-3H-indol-
3-ylidene]propane hydrazides 49-63 were synthesized 
by carrying out cyclization of compounds 31-45 with 48 
in presence of phosphorous oxychloride. These products 
were obtained in satisfactory yield and purity as studied on 
the thin layer chromatography and melting point studies. 
The structural confirmation was carried out on the basis 
of spectral studies, the IR spectra of these compounds 
exhibited absorbance for important functional groups, 
such as secondary amide at 3154 cm−1; the carbonyl group 
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is indicated at 1655 cm−1 and the C=N bond is reflected 
around 1618 cm−1. These groups are common to all the 
molecules from final derivatives. The 1H NMR spectra of 
these compounds exhibited several characteristic NMR 
shifts. The ethylene protons were observed around d 2.00 
to 3.85 ppm; the aromatic protons were observed within the 
range of d 7.00 to 8.50 ppm, representing the phenyl ring 
and the indole aromatic nucleus. Compound 50 presented 
with a hydroxyl proton at d 9.49 ppm. These compounds 
were also analysed for their mass spectral characteristic 
and was found to be in good agreement with the results 
obtained for compound 50, which exhibited molecular 
mass of [M + H]+ 378.11 in the electron spray ionisation 
with positive mode of mass spectrometry.
All the synthesized compounds of the final series 49-63 
were screened for in vitro anti-inflammatory activity based 
on assay developed by Mizushima and Kobayashi.19 This 
assay is also known as the protein albumin denaturation test 
as it involves the determination of percentage protection from 
denaturation of protein and thus its stabilization ultimately 
the inhibition of inflammation. The relativity of absorbance 
between test samples (compounds 49-63) with respect to 
control, designated the stabilization of protein and thus the 
inhibition of heat-induced protein (albumin) denaturation or 
the inhibition by derivatives and reference drug indomethacin. 
The increase in absorbance in the test compounds indicated 
better stabilization of proteins compared to standard drug 
indomethacin and the blank. Compounds 50 and 51 exhibited 
absorbance of 0.0409 and 0.0407 accounting for a 66.59 and 
66.19% of denaturation, respectively. These are highest in 
this series of compounds followed by 65.87% (0.0403) for 
58, then 65.63% (0.0403) for 55, and 65.07% (0.0402) for 53 
(Table. 1). Other derivatives have also shown better percent 
of denaturation, which is in the range of 54.12 to 64.16%; 
the standard drug indomethacin has exhibited percent of 
denaturation of 82.14% (0.0510). These results indicate 
that all the compounds have potential anti-inflammatory 
activity since the least active compound is also exhibiting a 
percent denaturation of 54.12%, with more than fifty percent, 
whereas the most active compound presents inhibition of 
66.59%. In vitro assay displayed some features of this series 
with respect to substitutions; methyl, hydroxy, methoxy, 
chloro and nitro substituted derivatives, such as 50, 51, 
58 and 55, possess good anti-inflammatory activity. Since 
these compounds were studied at various concentrations 
(25, 50, 100 and 200 μg mL−1), it was decided to perform 
in vivo activity on all the derivatives to determine their anti-
inflammatory activity.
Compounds were evaluated for their in vivo anti-
inflammatory activity by carrageenan induced paw edema 
method. The protocol of animal experiments was approved 
by the Institutional Animal Ethics Committee (IAEC). 
The compounds were tested at 100 mg kg−1 oral dose and 
were compared with the standard drug indomethacin at 
100 mg kg−1 oral dose. The tested compounds showed 
anti-inflammatory activity ranging from 13.9 to 45.5% after 
3 h (Table 1). The anti-inflammatory results revealed that 
compounds 50, 51 and 58 exhibited good anti-inflammatory 
activity whereas compounds 53 and 55 showed moderate 
activity, and compounds 63, 62, 57, 54 and 49 showed 
low activities when compared with standard drug 
(indomethacin). These results illustrate that compounds 
substituted with methyl 51, hydroxy 50, methoxy 53 and 
nitro 55 at position 5 of the 1,3,4-oxadiazole ring system 
showed good anti-inflammatory activity, having maximum 
percentage of inhibition in edema. Surprisingly, the halogen 
derivatives such as chloro 54, fluoro 57, bromo 63 and 
acetyl 56 showed low activity. This indicates that the 
compound having p-substituted electron withdrawing 
groups may enhance anti-inflammatory activity and 
electron releasing groups diminished the activity. The 
activity declines with replacement of electronegative 
group by electropositive group. It is noteworthy that NO2 
substitution of 3-nitrophenyl in 52 and 4-nitrophenyl in 55 
induce remarkable change in the activity, i.e., compound 
substituted with 3-nitrophenyl 52 showed low activity while 
compound substituted with 4-nitrophenyl 55 showed good 
activity. So, p-substituted derivatives favour good activity 
than m-substituted derivatives.
The analgesic activity of the synthesized compounds 
was evaluated by hot plate test according to Eddy and 
Leimbach.21 The compounds were tested at 100 mg kg−1 
oral dose and were compared with the standard drug 
indomethacin at 100 mg kg−1 oral dose. The tested 
compounds showed analgesic activity ranging from 
25.13 to 84.11% (Table 1) after 90 min time cycle for 
the series of compounds under study. The analgesic 
screening results revealed that compounds 50, 51 and 
52 showed good analgesic activity whereas compounds 
49 and 61 showed moderate activity and compounds 
56 and 57 showed low activity when compared with 
standard drug. The results illustrate that compounds 
substituted with 3-nitrophenyl 52 at position 5 of the 
1,3,4-oxadiazole ring system showed good analgesic 
activity having elevated percentage increase in reaction 
time following the compounds 50 and 51 with maximum 
activity. In addition, compounds substituted with 
phenyl 49 and 2-fluorophenyl 61 showed moderate 
activities while compound substituted with 2,3-dimethoxy 
53, 4-chlorophenyl 54 and 4-nitrophenyl 55 showed 
low activity. This indicates that the compounds having 
p-substituted and m-substituted electron withdrawing 
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groups may enhance analgesic activity and electron 
releasing groups diminish the activity. From the above 
discussion, it is clear that compound substituted with 
4-fluorophenyl 57 was found to be a fair anti-inflammatory 
agent with poor analgesic activity. These results suggest 
that unlike the substitution on indomethacin, the 
1,3,4-oxadiazole ring system behaves differently and 
suggests for substitution with electron donating group 
(EDG) on the ring system. 
The ulcerogenic activity was performed according to 
Cioli et al.28 and reports published earlier from our lab.18 
Those compounds, which showed good results in anti-
inflammatory and analgesic activity, were screened for 
their ulcerogenic activity. The tested compounds exhibited 
activity in the range of 0.14 to 0.56, whereas standard drug 
indomethacin presented very high severity index of 1.25. 
Results of this activity indicate that compound 50 and 
51 have a severity index of 0.35 and 0.56, respectively. 
Compounds 49 and 61 exhibit severity index of 0.24 and 
0.39, respectively, which is the lowest compared to other 
tested compounds; these compounds lack good anti-
inflammatory activity. This experiment clearly indicates 
that 50 and 51 are better tolerated derivative of this series 
and are far safer than the standard drug indomethacin with 
respect to the ulcerogenic effect. 
Indole is a very well-known nucleus and its derivative 
indomethacin is known to possess anti-inflammatory 
activity and used in therapy since last forty years. 
Accordingly, we proposed and derived several hybrids 
consisting of indole and oxadizole nuclei as inhibitor of 
the COX receptor, which is the target receptor for nearly 
all the NSAIDs. On the basis of in vitro and in vivo 
studies, it was found that compounds 50 and 51 exhibit 
good anti-inflammatory and analgesic activity. In order 
to investigate the molecular interactions and binding 
modes of some of the synthesized derivatives like 50, 
51, 53, 55 and 62, we docked these derivatives with 
COX enzyme (PDB code 4Z0L)29 using licensed version 
of Vlife MDS 4.32 software tools.22 This COX-2 receptor 
was used for our study because of two reasons: first, this 
complex provides with a indole derivative, which can act 
as a reference molecule for docking; and the second reason 
was the similarity with our animal model. Prior to carrying 
out docking the COX-2 receptor was prepared for docking 
by removing the ligands in complex but the water molecules 
were retained for this particular study. The receptor was 
prepared by removing the already bound ligand and then 
repaired with for missing residues by Biopredicta© tool. 
COX-2 is a homodimer and contains identical residues, 
active sites and channels; therefore, we employed a single 
chain for our study. This model was validated on the basis of 
Ramchandran Plot analysis and was found to be satisfactory 
with the core and allowed count of about 98% including 
glycine and proline residues. This model was saved and 
further employed for carrying out docking studies. 
The docking was carried out for all synthesized 
compounds. Figure 2 exhibits the docking mode of 
compound 50 and 51 with all three important interactions 
like hydrogen bonding, hydrophobic interaction and the 
Van der Waals forces interactions. Three compounds, 50, 51 
and 53, have exhibited good activity with 50 and 51 being 
most active followed by the other. This was also observed 
with the results of molecular docking; the energies for 50 
and 51 were found to be −4.44 and −4.37, respectively, 
which is highest in the series of synthesized derivatives 
and comparable to standard drug indomethacin with score 
of −4.47 (Table 1). Compound 50 revealed that it binds to 
the active site of COX-2 receptor by forming hydrogen 
bond with GLY536 (bond length: 2.125 Å) and TYR373 
(bond length: 2.325 Å; Figure 2a, 50). Hydrophobic 
interactions were found to be mostly between GLN374 
with bond length of 4.635, 4.538 and 4.045, ARG376 
(Figure 2b, 50). It also formed multiple Van der Waal 
interactions with the receptor amino acids having bond 
length between 2 to 3.9 Å (Figure 2c, 50). Compound 51 
prominently displayed that it binds to the active site of 
COX-2 receptor by forming two hydrogen bonds with 
ASN375 (bond length: 2.108 and 2.286 Å; Figure 2a, 51). 
Hydrophobic interactions were found to be mostly among 
GLN374A, GLN374B, ASN375B, TYR373B, PRO127A, 
SER541B and ASN537B with bond length between 2.342 
and 4.828 (Figure 2b, 51). It also formed multiple Van der 
Waal interactions with the receptor amino acids having 
bond length between 2.0 and 3.9 Å (Figure 2c, 51).
The Van der Waal interactions were observed between 
the receptor and indole nucleus plus its substituted 
oxadiazole moiety. This molecule seemed to lay on both 
the chains as A and B of the homodimer, it is illustrated 
by fact that interactions were observed with GLY536A, 
PHE142B, TRP139B, PRO538A, ASN537A, GLN374A, 
ASN375A, ARG376B, ASN373B, GLY536B, TYR373B, 
PRO127A, PRO538B and ASN537B with bond length 
from 2.1 to 3.9 Å. Compounds 53 and 55 were found to 
show good dock score of −4.01 and −3.05, respectively; 
these compounds also had interaction with TRP139B, 
PRO538A, ASN537A, GLN374A, ASN375A, ARG376B, 
ASN373B and ASN 537B, forming the hydrophobic and 
Van der Waals interactions. In case of compounds 62 and 
63, the dock score was found to be comparatively high 
viz, −4.04 and −4.46, respectively, but they did not show a 
good biological activity profile in wet lab studies. So, this 
dock score might be due to the presence of halogens, such 
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as the bromine. It is observed that presence of methyl or 
hydroxyl groups causes rise in activity as well as it can be 
seen that nitro substitution on the 1,3,4-oxadiazole causes 
increase in the activity. The docking of newly designed 
molecules has also presented their entry into deep sited 
region of the receptor, probably on the confluence of both 
the chains. Thus, it is considered that presence of indole 
and oxadiazole ring in the single molecule is beneficial for 
the activity, but the presence of halogen such as fluorine 
or chlorine on the 1,3,4-oxadiazole reduces the activity. 
Further, it is also noted that the position of substitution on 
the phenyl ring has great contribution towards the activity 
as an anti-inflammatory and analgesic compound. 
In this preliminary communication, we have presented 
synthesis and pharmacological evaluation of novel N’-
(2-oxoindolin-3-ylidene)-3-(5-substituted phenyl-1,3,4-
oxadiazol-2-yl)propane hydrazide derivatives 49-63, 
obtained following a five step reactions. The reactions 
were simple and follow-up procedure resulted in pure 
compounds with satisfactory yield. In vitro and in vivo anti-
inflammatory activity revealed that compounds 50 and 51 
exhibit comparable inhibition to standard drug indomethacin 
with added advantage of very less possibility of ulceration. 
These compounds were found to be good analgesic agents 
also when compared with standard drug. These molecules 
exhibited that methyl and hydroxy substituted molecules 
are better tolerated as well as present better activity when 
compared to their chloro and fluoro counterparts. The 
molecular docking studies on these molecules also verified 
the wet lab results, compounds 50 and 51 exhibited hydrogen 
bonding, hydrophobic interactions as well as Van der Waals 
interactions. The dock scores and binding energy were found 
to be in good agreement with the pharmacological results. 
This work need to be further elaborated with respect to 
number of molecules, their versatility, animal models, and 
structure activity relationship studies and most importantly 
with respect to the pK/pD studies. 
Conclusions
In conclusion, we have described the design and 
synthesis of novel oxadiazolyl-2-oxoindolinylidene 
propane hydrazides as amide tethered hybrids of indole 
and oxadiazole and their evaluation for anti-inflammatory 
and analgesic activity. The compounds were successfully 
synthesised following five step reaction to yield fifteen 
Figure 2. Molecular docking results for compound 50 (above) and 51 (below): (a) hydrogen bond interaction; (b) hydrophobic interaction; (c) Van der 
Waals interaction.
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derivatives as 3-(5-substituted-1,3,4-oxadiazol-2-yl)-N’-[2-
oxo-1,2-dihydro-3H-indol-3-ylidene]propane hydrazides. 
In vitro and in vivo studies have exhibited final derivatives 
50 and 51 as highly promising molecules with severity 
index of 0.35 and 0.56, respectively, encouraging for an 
analgesic compound. The hydroxy and methyl substitutions 
on phenyl ring system provided with active compounds 
having percentage of inhibition of 84.11 and 83.17%, 
respectively, compared to standard the drug at 85.84%. 
Molecular docking studies are also in agreement with 
the pharmacological evaluation with potent compounds 
exhibiting dock score of −4.44. It can be stated that these 
compounds can be further studied for their structure-
activity relationship (SAR) studies and developed into 
potential lead molecules. 
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